Ceftobiprole for Treatment of Complicated Staphylococcus aureus Bacteremia
Open accessThe DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Abstract
Ceftobiprole is a cephalosporin that may be effective for treating complicated Staphylococcus aureus bacteremia, including methicillin-resistant S. aureus. Download a PDF of the Research Summary. In this phase 3, double-blind, double-dummy, noninferiority trial, adults with complicated S. aureus bacteremia were randomly assigned in a 1:1 ratio to receive ceftobiprole at a dose of 500 mg intravenously every 6 hours for 8 days and every 8 hours thereafter, or daptomycin at a dose of 6 to 10 mg per kilogram of body weight intravenously every 24 hours plus optional aztreonam (at the discretion of the trial-site investigators). The primary outcome, overall treatment success 70 days after randomization (defined as survival, bacteremia clearance, symptom improvement, no new S. aureus bacteremia–related complications, and no receipt of other potentially effective antibiotics), with a noninferiority margin of 15%, was adjudicated by a data review committee whose members were unaware of the trial-group assignments. Safety was also assessed. Of 390 patients who underwent randomization, 387 (189 in the ceftobiprole group and 198 in the daptomycin group) had confirmed S. aureus bacteremia and received ceftobiprole or daptomycin (modified intention-to-treat population). A total of 132 of 189 patients (69.8%) in the ceftobiprole group and 136 of 198 patients (68.7%) in the daptomycin group had overall treatment success (adjusted difference, 2.0 percentage points; 95% confidence interval [CI], −7.1 to 11.1). Findings appeared to be consistent between the ceftobiprole and daptomycin groups in key subgroups and with respect to secondary outcomes, including mortality (9.0% and 9.1%, respectively; 95% CI, −6.2 to 5.2) and the percentage of patients with microbiologic eradication (82.0% and 77.3%; 95% CI, −2.9 to 13.0). Adverse events were reported in 121 of 191 patients (63.4%) who received ceftobiprole and 117 of 198 patients (59.1%) who received daptomycin; serious adverse events were reported in 36 patients (18.8%) and 45 patients (22.7%), respectively. Gastrointestinal adverse events (primarily mild nausea) were more frequent with ceftobiprole. Ceftobiprole was noninferior to daptomycin with respect to overall treatment success in patients with complicated S. aureus bacteremia. (Funded by Basilea Pharmaceutica International and the U.S. Department of Health and Human Services; ERADICATE ClinicalTrials.gov number, NCT03138733.) QUICK TAKE VIDEO SUMMARYCeftobiprole for Complicated S. aureus Bacteremia 02:15
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Tong, S. Y. C., Davis, J. S., Eichenberger, E., Holland, T. L., & Fowler, V. G. (2015) · Clinical Microbiology Reviews · doi:10.1128/cmr.00134-14 · Cited by 5,192
Self-citationProposed Modifications to the Duke Criteria for the Diagnosis of Infective Endocarditis
Li, J. S., Sexton, D. J., Mick, N., Nettles, R., Fowler, V. G., Ryan, T., Bashore, T., & Corey, G. R. (2000) · Clinical Infectious Diseases · doi:10.1086/313753 · Cited by 4,027
Self-citation
Cited by
ESKAPE pathogens: antimicrobial resistance, epidemiology, clinical impact and therapeutics
Miller, W. R., & Arias, C. A. (2024) · Nature Reviews Microbiology · doi:10.1038/s41579-024-01054-w · Cited by 862
Antibiotic treatment for 7 versus 14 days in patients with bloodstream infections
The BALANCE Investigators (2025) · New England Journal of Medicine · doi:10.1056/nejmoa2404991 · Cited by 158
The real crisis in antimicrobial resistance: failure to anticipate and respond
Bonomo, R. A., Perez, F., Hujer, A. M., Hujer, K. M., & Vila, A. J. (2024) · Clinical Infectious Diseases · doi:10.1093/cid/ciad758 · Cited by 33
“As we were re-minded by a recent randomized controlled trial of complicated Staphylococcus aureus bacteremia, a more commonly encountered and yet serious infection, overall treatment success with active antibiotics only occurs in 70% of cases [28].”
MethodRole of Metal Availability in Modulating Antibiotic Efficacy
Velez, A. (2025) · The University of North Carolina at Chapel Hill University Libraries · doi:10.17615/qh5n-2n35
Metadata
- Authors
- Holland, T. L., Cosgrove, S. E., Doernberg, S. B., Jenkins, T. C., Turner, N. A., Boucher, H. W., Pavlov, O., Titov, I., Kosulnykov, S., Atanasov, B., Poromanski, I., Makhviladze, M., Anderzhanova, A., Stryjewski, M. E., Assadi Gehr, M., Engelhardt, M., Hamed, K., Ionescu, D., Jones, M., Saulay, M., Smart, J., Seifert, H., & Fowler, V. G.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2023-10-12
- Volume
- 389
- Issue
- 15
- Pages
- 1390-1401
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W4387077543
- Cited by
- 115
- References
- 2
- FWCI
- 21.56
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Ceftobiprole for Treatment of Complicated Staphylococcus aureus Bacteremia. https://app.cochat.ai/papers/10.1056/nejmoa2300220
- The paper
- Holland, T. L., Cosgrove, S. E., Doernberg, S. B., Jenkins, T. C., Turner, N. A., Boucher, H. W., Pavlov, O., Titov, I., Kosulnykov, S., Atanasov, B., Poromanski, I., Makhviladze, M., Anderzhanova, A., Stryjewski, M. E., Assadi Gehr, M., Engelhardt, M., Hamed, K., Ionescu, D., Jones, M., . . . Fowler, V. G. (2023). Ceftobiprole for Treatment of Complicated Staphylococcus aureus Bacteremia. New England Journal of Medicine. https://doi.org/10.1056/nejmoa2300220
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.